| Rank |
Status |
Study |
| 1 |
Unknown †
|
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
| Conditions: |
Schizophrenia; Schizoaffective Disorder |
| Interventions: |
Drug: long-acting injectable risperidone; Drug: long acting injectable risperidone |
| Outcome Measures: |
The primary end point will be change in PANSS Positive Subscale Score in the high dose group using a mixed model ANOVA; change in PANSS; time to discontinuation for lack of efficacy and tolerability; change in cognitive domain scores; comparative incidence and time course of EPS, hyperprolactinemia, plasma lipids, weight gain, and other side effects between treatments |
|
| 2 |
Unknown †
|
Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning
| Condition: |
Schizophrenia |
| Interventions: |
Drug: Risperidone; Drug: Paliperidone |
| Outcome Measure: |
Comparison of BOLD signal activation and FDG metabolism of the DLPFC, superior temporal gyrus and amygdala, and their interaction between Invega and Risperdal |
|
| 3 |
Recruiting
|
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
| Conditions: |
Psychotic Disorders; Schizophrenia; Bipolar Disorder; Depressive Disorder |
| Interventions: |
Drug: Aripiprazole, oral formulation; Drug: Olanzapine, oral formulation; Drug: Paliperidone, oral formulation; Drug: Paliperidone, LAI; Drug: Quetiapine, oral formulation; Drug: Risperidone, oral formulation; Drug: Risperidone, LAI |
| Outcome Measures: |
Aripiprazole concentration in venous and capillary plasma; Paliperidone concentration in venous and capillary plasma; Olanzapine concentration in venous and capillary plasma; Quetiapine concentration in venous and capillary plasma; Risperidone concentration in venous and capillary plasma; Number of participants with an adverse event as a measure of safety |
|
| 4 |
Recruiting
|
A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis
| Condition: |
Methamphetamine Dependence |
| Interventions: |
Drug: paliperidone; Drug: Risperidone |
| Outcome Measures: |
The severity of psychosis; Clinical general status |
|
| 5 |
Recruiting
|
Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
| Condition: |
Schizophrenia (Recent-onset) |
| Interventions: |
Drug: paliperidone palmitate; Drug: risperidone |
| Outcome Measures: |
Exacerbation or relapse of psychotic symptoms; Cognitive functioning based on Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery; Role Functioning; Cognitive performance on test battery (MCCB); Insight (Awareness of Mental Disorder); Retention in treatment; Social functioning; Emotional reactivity on psychophysiological measures |
|
| 6 |
Recruiting
|
Risperidone and Desipramine in Alcohol Use and Schizophrenia
| Conditions: |
Schizophrenia; Alcoholism; Dual Diagnosis |
| Interventions: |
Drug: Risperidone + Desipramine; Drug: Risperidone + Placebo |
| Outcome Measure: |
Timeline Followback |
|
| 7 |
Recruiting
|
Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
| Conditions: |
Attention Deficit/Hyperactivity Disorder; Oppositional Defiant Disorder; Conduct Disorder |
| Interventions: |
Drug: Methylphenidate; Drug: Risperidone |
| Outcome Measures: |
Change from baseline of aggressive behaviors.; Clinical Global Impression - Improvement scale (CGI-I) questionnaire; ADHD-RS questionnaire; Children's Depression Rating Scale (CDRS) questionnaire; Young Mania Rating Scale (YMRS) questionnaire; Children Sleep Habits Questionnaire (CSHQ); Clinical Global Impression - Severity (CGI-S) questionnaire |
|
| 8 |
Unknown †
|
Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients
| Condition: |
Schizophrenia |
| Interventions: |
Other: active Risperidone and active rTMS; Other: active rTMS and sham Risperidone; Other: sham rTMS and active Risperidone |
| Outcome Measures: |
PANSS; Total AHRS score; HAMD Score; CGI; fMRI |
|
| 9 |
Not yet recruiting
|
Bioavailability of LY03004 and Risperdal® Consta®
| Conditions: |
Schizophrenia; Schizoaffective Disorder |
| Interventions: |
Drug: LY03004; Drug: Risperdal® Consta® |
| Outcome Measures: |
Cmax, Tmax, for Relative bioavailability of LY03004 compared to Risperdal® Consta®; Number of Participants with Adverse Events as a Measure of Safety and Tolerability; The change of the PANSS score for the Preliminary efficacy of LY03004 |
|
| 10 |
Unknown †
|
Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone
| Condition: |
Schizophrenia |
| Interventions: |
Drug: Sertindole; Drug: Risperidone |
| Outcome Measures: |
cognitive functioning; Discontinuation due to all causes, symptomatology and adverse events. |
|
| 11 |
Unknown †
|
Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior
| Condition: |
Autism |
| Intervention: |
Drug: Risperidone |
| Outcome Measure: |
Aberrant Behavior Checklist |
|
| 12 |
Recruiting
|
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
| Condition: |
Autistic Disorder |
| Interventions: |
Drug: Aripiprazole; Drug: Risperidone |
| Outcome Measure: |
To identify phenotypic and genetic traits that predict response to aripiprazole and risperidone in Autistic Disorder |
|
| 13 |
Recruiting
|
A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia
| Condition: |
Schizophrenia |
| Interventions: |
Drug: Paliperidone extended-release; Drug: Risperidone immediate-release |
| Outcome Measures: |
Change in category fluency score of cognitive function scale (Cognitive Abilities Screening Instrument, Chinese version [CASI C-2.0]) from baseline to Week 24; Change from baseline to Week 24 in score of Modified Wisconsin Card Sorting Test (MWCST) short version; Change from baseline in score of Continuous Performance Test (CPT); Change from baseline in score of Personal and Social Performance (PSP) scale; Change from baseline in score of Positive and Negative Syndrome Scale (PANSS); Change from baseline in score of Clinical Global Impression-severity (CGI-S) scale; Change from baseline in score of Medication Satisfaction Questionnaire (MSQ) |
|
| 14 |
Unknown †
|
Risperidone and Zotepine in the Treatment of Delirium
| Condition: |
Delirium |
| Intervention: |
Drug: Risperidone and Zolpidem for delirium |
| Outcome Measures: |
Delirium rating scale; MMSE, CGI, side effect profile, HRV |
|
| 15 |
Recruiting
|
Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
| Condition: |
Schizophrenia |
| Intervention: |
Drug: Risperidone ISM |
| Outcome Measures: |
Peak Plasma Concentration (Cmax) for Active Moiety; Trough Plasma Concentration (Cmin) for Active Moiety; Area under the curve to the last quantified concentration (AUClast) and Area under the curve extrapolated to infinity (AUC∞) for Active Moiety; Terminal rate constant (λz), Terminal half-life (t1/2) and Time to peak concentration (tmax) for Active Moiety; Peak Plasma Concentration (Cmax) for Risperidone and 9OH-Risperidone Moieties; Trough Plasma Concentration (Cmin) for Risperidone and 9OH-Risperidone Moieties; Occurrence, nature, onset time, duration, intensity, action taken, outcome and relationship to study drug of AEs as a Measure of Safety; Area under the curve to the last quantified concentration (AUClast) and Area under the curve extrapolated to infinity (AUC∞) for Risperidone and 9OH-Risperidone Moieties; Terminal rate constant (λz), Terminal half-life (t1/2) and Time to peak concentration (tmax) for Risperidone and 9OH-Risperidone Moieties; Area Under the Concentration-time Curve for To perform a descriptive comparison of the PK data between the gluteal and the deltoid muscle administration of the injectable ISM formulation |
|
| 16 |
Recruiting
|
Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
| Conditions: |
Delirium; Agitation |
| Interventions: |
Drug: Risperidone; Drug: Trazodone; Drug: Placebo |
| Outcome Measures: |
The number of days patients are without delirium during the study period (delirium-free days); Daily prevalence of delirium as indicated by a positive Confusion Assessment Method in the ICU (CAM-ICU); Resolution of delirium as indicated by a negative Confusion Assessment Method in the ICU (CAM-ICU) for more than 24 hours; The number of patients who require rescue medications, the type of rescue medications utilized, and the amount of rescue medications per day; The number of patients who receive sedative agents, amount of midazolam equivalents per day, and the number of days in which patients receive a sedative agent; The number of patients who receive pain medications, amount of fentanyl equivalents per day, and the number of days in which patients receive a pain medication; The number of hours spent agitated (RASS score between +4 and +2) as a percent of the time that the study drug was administered; The number of hours spent excessively sedated or in a coma state (RASS score between -4 to -5) as a percent of the time that the study drug was administered; The duration of mechanical ventilation from initial intubation to extubation as long as the patient remained extubated for more than 48 hours.; The number of days that the patients were alive and breathing without assistance during the study period (ventilator-free days); The number of episodes and number of patients who experience clinically significant QTc prolongation (≥ 500 msec or an increase of more than 60 msec from baseline); The number of episodes and number of patients who experience clinically significant extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score); All-cause mortality and 28-day mortality |
|
| 17 |
Unknown †
|
Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia
| Conditions: |
Smoking Cessation; Schizophrenia |
| Interventions: |
Drug: Tropisetron; Drug: Placebo; Drug: Risperidone |
| Outcome Measures: |
Cognitive deficits as assessed by tests measuring the MATRICS cognition domains; Negative schizophrenic symptoms; Reduction in side effects of risperidone; Abnormality in P50 inhibition; Nicotine use among all participants who smoke |
|
| 18 |
Recruiting
|
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
| Condition: |
Schizophrenia |
| Interventions: |
Drug: RO5545965; Other: Placebo; Drug: risperidone |
| Outcome Measures: |
Incidence of adverse events; Health of the patients, assessed through a complete medical examination including physical examination, electrocardiogram (ECG) and vital signs.; Pharmacokinetics: Plasma area under the concentration-time curve (AUC) of RO5545965; Pharmacokinetics: Plasma area under the concentration-time curve (AUC) of risperidone |
|
| 19 |
Not yet recruiting
|
Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia
| Condition: |
Schizophrenia |
| Interventions: |
Drug: Paliperidone Palmitate; Drug: Risperidone |
| Outcome Measures: |
Intracortical myelin; Cognition; Biomarker |
|
| 20 |
Unknown †
|
Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
| Conditions: |
Schizophrenia; Schizoaffective Disorder |
| Interventions: |
Drug: Risperdal Consta (drug); Behavioral: Social Skills Training |
| Outcome Measures: |
Scores on an analogue measure of responsiveness to skills training.; Scores on a measure of skills acquisition and performance pre-post a 3-month skills training group.; Interview measures of social functioning.; Neurocognitive functioning.; Symptomatology. |
|
